Genovis AB (publ.) (STO: GENO)

Market Cap	1.66B
Revenue (ttm)	127.86M
Net Income (ttm)	17.25M
Shares Out	65.47M
EPS (ttm)	0.26
PE Ratio	96.02
Forward PE	59.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,283
Open	24.80
Previous Close	25.50
Day's Range	24.80 - 26.10
52-Week Range	22.50 - 56.20
Beta	1.62
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 37
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2023, Prevas AB's revenue was 1.48 billion, an increase of 11.94% compared to the previous year's 1.32 billion. Earnings were 118.20 million, a decrease of -0.38%.